文献速递脊柱关节炎

利用两项古塞奇尤单抗治疗生物制剂初治银屑病关节炎患者的III期临床试验数据,通过机器学习分析识别银屑病关节炎表型

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA.
PubMed 文献 · RMD Open · 2023-01-01

该事后分析汇总DISCOVER-1和DISCOVER-2两项III期试验中生物制剂初治的活动性银屑病关节炎患者数据,采用非负矩阵分解的无监督机器学习识别出8个表型聚类,各聚类在人口学、临床特征及古塞奇尤单抗治疗52周的反应上存在差异。

要点

  • 共识别8个银屑病关节炎表型聚类(n=661),涵盖足主导、手主导、指炎主导、附着点炎等类型。
  • 第24周最小疾病活动度反应在聚类2最高、聚类3/5/6最低;第52周聚类2最高、聚类5最低。
  • 第24和52周DAPSA低疾病活动度和缓解分别在聚类2最高,聚类4和聚类6最低。

核心结论

  • 无监督机器学习识别出8个银屑病关节炎表型聚类,其在人口学、临床特征和治疗反应上存在显著差异。
  • 作者认为未来此类数据可能有助于支持个体化治疗决策。

研究设计与样本

  • 对III期DISCOVER-1和DISCOVER-2临床试验中接受古塞奇尤单抗100 mg每8周或每4周治疗的生物制剂初治活动性银屑病关节炎患者数据进行事后回顾性分析。
  • 采用非负矩阵分解的无监督机器学习技术,以基线患者特征和临床观察为输入特征识别表型聚类,共纳入n=661例。

主要发现

  • 识别出8个聚类:聚类1(足主导)、聚类2(男性、超重、银屑病主导)、聚类3(手主导)、聚类4(指炎主导)、聚类5(附着点炎、大关节)、聚类6(附着点炎、小关节)、聚类7(中轴主导)、聚类8(女性、肥胖、大关节)。
  • 第24周最小疾病活动度反应在聚类2最高,在聚类3、5和6最低;第52周在聚类2最高,在聚类5最低。
  • 第24周和第52周DAPSA低疾病活动度和缓解分别在聚类2最高,在聚类4和聚类6分别最低。
  • 所有聚类在52周古塞奇尤单抗治疗期间均有所改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Psoriatic arthritis (PsA) phenotypes are typically defined by their clinical components, which may not reflect patients' overlapping symptoms. This post hoc analysis aimed to identify hypothesis-free PsA phenotype clusters using machine learning to analyse data from the phase III DISCOVER-1/DISCOVER-2 clinical trials. METHODS: Pooled data from bio-naïve patients with active PsA receiving guselkumab 100 mg every 8/4 weeks were retrospectively analysed. Non-negative matrix factorisation was applied as an unsupervised machine learning technique to identify PsA phenotype clusters; baseline patient characteristics and clinical observations were input features. Minimal disease activity (MDA), disease activity index for psoriatic arthritis (DAPSA) low disease activity (LDA) and DAPSA remission at weeks 24 and 52 were evaluated. RESULTS: Eight clusters (n=661) were identified: cluster 1 (feet dominant), cluster 2 (male, overweight, psoriasis dominant), cluster 3 (hand dominant), cluster 4 (dactylitis dominant), cluster 5 (enthesitis, large joints), cluster 6 (enthesitis, small joints), cluster 7 (axial dominant) and cluster 8 (female, obese, large joints). At week 24, MDA response was highest in cluster 2 and lowest in clusters 3, 5 and 6; at week 52, it was highest in cluster 2 and lowest in cluster 5. At weeks 24 and 52, DAPSA LDA and remission were highest in cluster 2 and lowest in clusters 4 and 6, respectively. All clusters improved with guselkumab treatment over 52 weeks. CONCLUSIONS: Unsupervised machine learning identified eight PsA phenotype clusters with significant differences in demographics, clinical features and treatment responses. In the future, such data could help support individualised treatment decisions.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Richette P, Vis M, Ohrndorf S, et al. Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA. RMD Open. 2023. PMID: 37001920. doi:10.1136/rmdopen-2022-002934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。